Evidence map›Paper›PMID 41917547›Full record

ArticleJournal of neuro-oncology2026

Photodynamic therapy using talaporfin sodium for grade 2/3 meningiomas: a preliminary study of safety, feasibility, and clinical outcomes.

Shinjiro Fukami, Jiro Akimoto, Kenta Nagai, Nobuyuki Nakajima, Norio Ichimasu, Ken Matsushima, Sho Onodera, Yuki Saito, Michihiro Kohno

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shinjiro FukamiDepartment of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-023, Japan. fukami@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0002-4456-1796
Jiro AkimotoDepartment of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-023, Japan.
Kenta NagaiDepartment of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-023, Japan.
Nobuyuki NakajimaDepartment of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-023, Japan.
Norio IchimasuDepartment of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-023, Japan.
Ken MatsushimaDepartment of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-023, Japan.
Sho OnoderaDepartment of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-023, Japan.
Yuki SaitoDepartment of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-023, Japan.
Michihiro KohnoDepartment of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-023, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAtypical and anaplastic (grade 2/3) meningiomas are associated with high recurrence rates and lack effective systemic therapies other than radiotherapy. Photodynamic therapy (PDT) using talaporfin sodium (TPS) generates selective cytotoxicity extending beyond resection margins and may improve local tumor control. Objective is to evaluate the feasibility, safety, and clinical outcomes of additional intraoperative PDT using TPS for grade 2/3 meningioma patients.

methodsNineteen patients with grade 2/3 meningiomas who underwent resection together with PDT at our institute between 2015 and 2025 were retrospectively analyzed. PDT was performed 22 to 26 h after intravenous TPS administration. Tumor location, pathology, Simpson resection grades, history of radiation therapy (RT), and outcomes were reviewed.

resultsOf the 19 patients, 18 had recurrent tumors, and 10 had prior RT. Tumor sites included skull base (8 patients), parasagittal sinus (6), convexity (2), falx (1), subcutaneous (1), and intraventricular (1). Histology revealed grade 2 (12 patients) and grade 3 (7), with Simpson I (3), II (6), III (2), and IV (8) resections. Median progression-free survival was 12.5 months, and median overall survival after PDT was 54.5 months. The prognosis was more favorable in RT- naïve patients than in those with a history of prior RT before PDT.

conclusionPDT combined with resection is a safe adjunctive strategy for grade 2/3 meningiomas. Our preliminary data suggest that its efficacy is limited in post-radiation recurrences, but it may delay disease progression when applied before RT. PDT should hence be considered as a therapeutic option for grade 2/3 meningiomas.

Indexed as

Meningeal NeoplasmsMeningiomaPhotochemotherapyPhotosensitizing AgentsPorphyrinsAdultAgedFeasibility StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalPrognosisPhotosensitizing AgentsPorphyrinsTalaporfinGrade 2/3 meningiomaPhotodynamic therapyRecurrenceSurgical resectionTalaporfin sodium

Identifiers

PMID41917547
PMCPMC13038455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.